Prothena Corporation plc (PRTA)
NASDAQ: PRTA · IEX Real-Time Price · USD
22.04
+0.62 (2.89%)
At close: May 2, 2024, 4:00 PM
24.24
+2.20 (9.98%)
After-hours: May 2, 2024, 7:59 PM EDT
Prothena Corporation Revenue
In the year 2023, Prothena Corporation had annual revenue of $91.37M with 69.50% growth. Revenue in the quarter ending December 31, 2023 was $316.00K, a -99.37% decrease year-over-year.
Revenue (ttm)
$91.37M
Revenue Growth
+69.50%
P/S Ratio
12.96
Revenue / Employee
$528,150
Employees
173
Market Cap
1.18B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 91.37M | 37.47M | 69.50% |
Dec 31, 2022 | 53.91M | -146.67M | -73.13% |
Dec 31, 2021 | 200.58M | 199.72M | 23,414.30% |
Dec 31, 2020 | 853.00K | 39.00K | 4.79% |
Dec 31, 2019 | 814.00K | -141.00K | -14.76% |
Dec 31, 2018 | 955.00K | -26.56M | -96.53% |
Dec 31, 2017 | 27.52M | 26.46M | 2,508.44% |
Dec 31, 2016 | 1.06M | -552.00K | -34.35% |
Dec 31, 2015 | 1.61M | -49.25M | -96.84% |
Dec 31, 2014 | 50.85M | 50.18M | 7,422.78% |
Dec 31, 2013 | 676.00K | -1.98M | -74.57% |
Dec 31, 2012 | 2.66M | 2.15M | 424.26% |
Dec 31, 2011 | 507.00K | -736.00K | -59.21% |
Dec 31, 2010 | 1.24M | - | - |
Dec 31, 2009 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Maravai LifeSciences Holdings | 288.95M |
MannKind | 198.96M |
Cronos Group | 87.24M |
Vir Biotechnology | 86.18M |
Immatics | 60.00M |
AbCellera Biologics | 38.03M |
Silence Therapeutics | 32.12M |
Bicycle Therapeutics | 26.98M |
PRTA News
- 1 day ago - Prothena to Report First Quarter 2024 Financial Results on May 8 - Business Wire
- 17 days ago - Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma - Business Wire
- 2 months ago - Prothena to Participate in Upcoming Healthcare Conferences - Business Wire
- 2 months ago - Prothena Appoints David Ford to Newly Created Chief People Officer Position - Business Wire
- 2 months ago - Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate - Business Wire
- 2 months ago - Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights - Business Wire
- 3 months ago - Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024 - Business Wire
- 4 months ago - Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs - Business Wire